- Home
- GAME vs PULM Comparison
GAME vs PULM Comparison
Compare GAME & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- PULM
- Stock Information
- Founded
- GAME 2011
- PULM 2003
- Country
- GAME United States
- PULM United States
- Employees
- GAME N/A
- PULM N/A
- Industry
- GAME
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- GAME
- PULM Health Care
- Exchange
- GAME Nasdaq
- PULM Nasdaq
- Market Cap
- GAME 74.8M
- PULM 20.5M
- IPO Year
- GAME 2009
- PULM N/A
- Fundamental
- Price
- GAME $0.98
- PULM $5.61
- Analyst Decision
- GAME Strong Buy
- PULM
- Analyst Count
- GAME 3
- PULM 0
- Target Price
- GAME $3.67
- PULM N/A
- AVG Volume (30 Days)
- GAME 25.4M
- PULM 11.7K
- Earning Date
- GAME 08-13-2025
- PULM 08-12-2025
- Dividend Yield
- GAME N/A
- PULM N/A
- EPS Growth
- GAME N/A
- PULM N/A
- EPS
- GAME N/A
- PULM N/A
- Revenue
- GAME $99,579,536.00
- PULM $1,921,000.00
- Revenue This Year
- GAME $6.08
- PULM N/A
- Revenue Next Year
- GAME $21.94
- PULM $134.88
- P/E Ratio
- GAME N/A
- PULM N/A
- Revenue Growth
- GAME 77.06
- PULM N/A
- 52 Week Low
- GAME $0.50
- PULM $1.78
- 52 Week High
- GAME $2.87
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- GAME 42.61
- PULM 28.72
- Support Level
- GAME $1.47
- PULM $5.60
- Resistance Level
- GAME $1.24
- PULM $6.15
- Average True Range (ATR)
- GAME 0.28
- PULM 0.29
- MACD
- GAME -0.10
- PULM -0.08
- Stochastic Oscillator
- GAME 0.07
- PULM 4.29
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged in revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. It's next generation media, entertainment, and technology helps creators and maximize their brand partners' return on investment. Its purpose-built platform provides marketing and creative services, offers data and analytics solutions, and amplifies awareness through FaZe Clan.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).